- We are working hard to come back as soon as possible.
- Nous travaillons dur pour revenir au plus vite.
- Wir arbeiten hart daran, so schnell wie möglich zurückzukommen
- Estamos trabajando duro para volver lo antes posible.
- Stiamo lavorando sodo per tornare il prima possibile.
- Wij werken hard om zo snel mogelijk weer terug te zijn.
Stacy Coen
Director/Board Member presso FIBROBIOLOGICS, INC.
Patrimonio netto: 81 075 $ in data 31/03/2024
Profilo
Stacy A.
Coen is an Independent Director at FibroBiologics, Inc. and the Chief Business Officer & Senior Vice President at ImmunoGen, Inc. She is also a Member of the Massachusetts Biotechnology Council, the Alliance for Regenerative Medicine, and a Trustee of the Huntington's Disease Society of America.
Previously, she held Vice President positions at Genzyme Corp.
and Editas Medicine, Inc. Coen received an undergraduate degree from the University of Massachusetts and an MBA from the University of Virginia Darden School of Business.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
FIBROBIOLOGICS, INC.
0.02% | 24/01/2024 | 7 500 ( 0.02% ) | 81 075 $ | 31/03/2024 |
Posizioni attive di Stacy Coen
Società | Posizione | Inizio |
---|---|---|
IMMUNOGEN, INC. | Corporate Officer/Principal | 03/06/2020 |
FIBROBIOLOGICS, INC. | Director/Board Member | 01/07/2021 |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Corporate Officer/Principal | - |
Massachusetts Biotechnology Council
Massachusetts Biotechnology Council Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Council is a premier life sciences and healthcare hub with over 1,600 members dedicated to preventing, treating, and curing diseases through transformative science and technology. The non-profit company is based in Cambridge, MA. MassBio works to advance policy and promote education while providing member programs, events, industry information, and services. The company's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. Founded in 1985 by James P. Sherblom, the CEO is Kendalle Burlin O'Connell. | Corporate Officer/Principal | - |
Huntington's Disease Society of America | Director/Board Member | - |
Precedenti posizioni note di Stacy Coen
Società | Posizione | Fine |
---|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
EDITAS MEDICINE, INC. | Corporate Officer/Principal | - |
Formazione di Stacy Coen
University of Massachusetts | Undergraduate Degree |
University of Virginia Darden School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
IMMUNOGEN, INC. | Health Technology |
EDITAS MEDICINE, INC. | Health Technology |
FIBROBIOLOGICS, INC. | Health Technology |
Aziende private | 4 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Massachusetts Biotechnology Council
Massachusetts Biotechnology Council Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Council is a premier life sciences and healthcare hub with over 1,600 members dedicated to preventing, treating, and curing diseases through transformative science and technology. The non-profit company is based in Cambridge, MA. MassBio works to advance policy and promote education while providing member programs, events, industry information, and services. The company's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. Founded in 1985 by James P. Sherblom, the CEO is Kendalle Burlin O'Connell. | Commercial Services |
Huntington's Disease Society of America | |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
- Borsa valori
- Insiders
- Stacy Coen